Ajooni Biotech financials

·UnclassifiedChart ›
Latest results Q1 FY27 · Apr–Jun 2026
Revenue
₹63.5cr+103.1% on Q1 FY26
Net profit
₹0.4cr−44.7% on Q1 FY26
EBITDA margin
2.6%+0.3 pts on Q1 FY26
EPS
₹0.01−50.0% on Q1 FY26

Quarterly results

Every quarter ›
₹ croreQ1 FY27Q1 FY26Change
Revenue63.531.3+103.1%
EBITDA1.70.7+133.7%
EBITDA margin2.6%2.3%+0.3 pts
Profit before tax0.71.0−36.3%
Net profit0.40.8−44.7%
EPS₹0.01₹0.02−50.0%

Over time

Q1 FY27 · Apr–Jun 2026latest
Revenue₹63.5 crNet profit₹0.4 crNet margin0.7%

Amounts on the left scale in ₹ crore; per cent on the right, dashed. L = lakh crore, K = thousand crore. Touch the chart to read any period.

Key numbersby financial year

₹ crore except per share
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
50.5————
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
0.40.46.80.4—
17.817.81.92.21.7
67.8————
21518211580.174.5
—+59.0%+43.2%+7.6%—
7.26.33.72.22.8
3.4%3.4%3.2%2.8%3.7%
4.54.02.61.41.8
4.04.33.42.21.1
1.8%2.4%2.9%2.7%1.5%
₹0.23₹0.25₹0.20₹0.13₹0.07
—+28.2%+56.0%+92.2%—
—−5.7−17.7−4.0−5.6
—−18.0−3.0−5.6−2.9
−23.8−23.8−20.7−9.6−8.4
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

AJOONI₹2.93

Ajooni Biotech Limited

· Unclassified
₹ CrorePeersTOUCHWOODRKECRAJMETBANKAAAKASHGANGAFORGEGLOBEAGROPHOSMcap ₹50.5 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
In ₹ Crore except Per Share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Market Capitalization————50.5
- Cash, Equiv & ST Investments—0.46.80.40.4
+ Total Debt1.72.21.917.817.8
Enterprise Value————67.8
Revenue74.580.1114.7182.4214.6
Growth %, YoY—+7.6+43.2+59.0—
EBITDA2.82.23.76.37.2
Margin %3.712.793.223.433.36
EBIT1.81.42.64.04.5
Net Income1.12.23.44.34.0
Margin %1.512.702.942.371.84
EPS, Adj (current shares)0.070.130.200.250.23
Growth %, YoY—+92.2+56.0+28.2—
Cash from Operations-5.6-4.0-17.7-5.7—
Capital Expenditures-2.9-5.6-3.0-18.0—
Free Cash Flow-8.4-9.6-20.7-23.8-23.8
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Ajooni Biotech financials and key ratios

Prices at the 30 October 2026 close · figures from the company's filings with NSE

Ajooni Biotech (NSE: AJOONI) had a market capitalisation of ₹49.4 crore at the 30 October 2026 close (₹2.87 a share), a PE ratio of 12.5 on the last four quarters' profit and a price-to-book ratio of 0.54. In FY26 its consolidated net profit was ₹4.3 crore on revenue of ₹182 crore; in Q1 FY27 (April–June 2026) it was ₹43 lakh, down 44.7% year on year. Its debt-to-equity ratio was 0.19 on 31 March 2026. Promoters held 30.53% of the shares on 30 September 2026.

Ajooni Biotech Q1 FY27 results
filed 14 August 2026
Share price used
₹2.87 · 30 October 2026 close
Latest balance sheet
31 March 2026
Shareholding pattern
30 September 2026

Ajooni Biotech at a glance · consolidated

Market cap
₹49.4 Crat ₹2.87 · 30 Oct close
PE ratio (last 4 quarters)
12.511.4 on FY26 profit
Price to book (PB)
0.54book value ₹5.29 a share
ROE (FY26)
4.8%−0.3 pts vs FY25ROCE 4.4%
Debt to equity
0.19net debt ₹17.3 Cr
Promoter holding
30.53%+3.6 pts vs 30 Jun 202630 September 2026
Net worth
₹91.2 Cr+3.5% vs 31 Mar 202531 March 2026
Free cash flow (FY26)
−₹23.8 Cr
EPS (FY26)
₹0.25

Questions

What is the Ajooni Biotech PE ratio today?

Ajooni Biotech's PE ratio is 12.5 at the 30 October 2026 close (₹2.87 a share): a market capitalisation of ₹49.4 crore divided by consolidated net profit of ₹4 crore over the last four quarters (Q2 FY26 to Q1 FY27). On FY26 net profit (₹4.3 crore) it is 11.4.

What is the Ajooni Biotech debt to equity ratio?

Ajooni Biotech's debt-to-equity ratio was 0.19 on 31 March 2026: borrowings of ₹17.8 crore against total equity of ₹91.2 crore. A year earlier, on 31 March 2025, it was 0.02.

What is the Ajooni Biotech net worth?

Ajooni Biotech's net worth — shareholders' equity in its consolidated balance sheet — was ₹91.2 crore on 31 March 2026, up 3.5% from ₹88.1 crore a year earlier. Its market value is a different figure: a market capitalisation of ₹49.4 crore at the 30 October 2026 close.

What is the Ajooni Biotech PB ratio (price to book value)?

Ajooni Biotech's price-to-book (PB) ratio is 0.54 at the 30 October 2026 close: a market capitalisation of ₹49.4 crore divided by shareholders' equity (book value) of ₹91.2 crore on 31 March 2026. That is a book value of ₹5.29 per share against a share price of ₹2.87.

What is the Ajooni Biotech ROE and ROCE?

In FY26, Ajooni Biotech's return on equity (ROE) was 4.8% and its return on capital employed (ROCE) was 4.4%. ROE is net profit divided by average shareholders' equity (the start and end of the year); ROCE is operating profit (EBIT) divided by average capital employed (total assets less current liabilities). In FY25, ROE was 5.2% and ROCE 3.9%.

What is the Ajooni Biotech book value per share?

Ajooni Biotech's book value per share was ₹5.29 on 31 March 2026: shareholders' equity of ₹91.2 crore divided by the 17.22 crore shares in issue, up 3.5% from ₹5.11 a year earlier. The share price at the 30 October 2026 close was ₹2.87.

What is the Ajooni Biotech market cap?

Ajooni Biotech's market capitalisation was ₹49.4 crore at the 30 October 2026 close: 17.22 crore shares at ₹2.87 each.

Is Ajooni Biotech debt free?

No. Ajooni Biotech had borrowings of ₹17.8 crore on 31 March 2026 (consolidated balance sheet), a debt-to-equity ratio of 0.19. Its cash and current investments were ₹42 lakh, so its net debt was ₹17.3 crore.

What is the Ajooni Biotech EPS?

Ajooni Biotech's basic earnings per share (EPS) were ₹0.25 in FY26, against ₹0.20 in FY25.

What is the Ajooni Biotech promoter holding?

Promoters held 30.53% of Ajooni Biotech on 30 September 2026, up 3.64 percentage points from 26.89% the previous quarter and up 3.64 percentage points from 26.89% a year earlier, according to the shareholding pattern filed with NSE.

What is the Ajooni Biotech shareholding pattern?

On 30 September 2026, Ajooni Biotech's shares were held by promoters 30.53% and retail and other non-institutional investors 69.47%.

What is the Ajooni Biotech free cash flow?

In FY26, Ajooni Biotech generated ₹5.7 crore of cash from operations and spent ₹18 crore on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of −₹23.8 crore. In FY25 it was −₹20.7 crore.

What are the Ajooni Biotech latest quarterly results?

Ajooni Biotech's latest results are for Q1 FY27 (April–June 2026), filed on 14 August 2026: consolidated net profit ₹43 lakh, down 44.7% from ₹78 lakh in Q1 FY26; revenue from operations ₹63.5 crore, up 103.1% year on year.

What is the Ajooni Biotech revenue and profit in FY26?

In FY26 (April 2025–March 2026), Ajooni Biotech's consolidated net profit was ₹4.3 crore, up 28.2% from ₹3.4 crore in FY25, on revenue from operations of ₹182 crore (up 59.0%). Over three years, from FY23, net profit was up 284.3%.

When are the Ajooni Biotech next results?

Ajooni Biotech has not yet announced the date of its Q2 FY27 results (July–September 2026); under SEBI's listing rules (Regulation 33) they are due by 14 November 2026.

How does Ajooni Biotech compare with its peers?

On FY26 consolidated figures, against Touchwood Entertainment and Rajnandini Metal: Ajooni Biotech's operating margin of 2.2% is the second highest of the three (Touchwood Entertainment 7.2%, Rajnandini Metal 0.7%; peer average 4.0%); its return on equity of 4.8% is the second highest of the three (Touchwood Entertainment 9.6%, Rajnandini Metal −0.6%; peer average 4.5%); its revenue growth over three years of 34.8% a year is the highest of the three (Touchwood Entertainment 26.7% a year, Rajnandini Metal −36.5% a year; peer average −4.9% a year).

Ajooni Biotech vs Touchwood Entertainment: how do they compare?

In FY26, Ajooni Biotech earned net profit of ₹4.3 crore on revenue of ₹182 crore, against ₹4 crore on ₹74.6 crore for Touchwood Entertainment. Ajooni Biotech's operating margin was 2.2% (Touchwood Entertainment 7.2%) and its return on equity 4.8% (Touchwood Entertainment 9.6%). At the 30 October 2026 close, Ajooni Biotech's market capitalisation was ₹49.4 crore against ₹59.1 crore for Touchwood Entertainment, and its PE ratio on FY26 profit 11.4 against 14.6.

Where do these Ajooni Biotech figures come from?

From Ajooni Biotech's own consolidated results, balance sheets and shareholding patterns filed with NSE, and NSE prices (the latest used here: the 30 October 2026 close). Ratios are calculated by Alphave from those filings as each answer describes.

Consolidated figures from the company's filings with NSE; prices are NSE closing prices.